Transapical Beating-Heart Septal Myectomy in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Nonobstructive Hypertrophic Cardiomyopathy
About this trial
This is an interventional treatment trial for Nonobstructive Hypertrophic Cardiomyopathy focused on measuring Nonobstructive Hypertrophic Cardiomyopathy, Septal Myectomy, Mitral Regurgitation, Transapical, Off-pump, Minimally invasive
Eligibility Criteria
Inclusion Criteria: Patients whose maximal ventricular septal wall thickness ≥ 15 mm. Patients with heart function of New York Heart Association ≥ class II. Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies. Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form Exclusion Criteria: Patients who were pregnant. Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-heart surgery. Patients who had severe heart failure with left ventricle ejection fraction < 40%. Patients whose estimated life expectancy < 12 m. Patient who were non-compliant. Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.
Sites / Locations
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting
Arms of the Study
Arm 1
Experimental
Nonbstructive Hypertrophic Cardiomyopathy
Transapical beating-heart septal myectomy for the patient with nonobstructive hypertrophic cardiomyopathy and Heart Failure.